Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1265

10.17650/1726-9776-2007-0-2-61-63

DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER

ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы

Adjuvant hormonal therapy as radical treatment of locally advanced prostate cancer

Адъювантная гормональная терапия как метод радикального лечения у больных местно-распространенным раком предстательной железы

Alekseyev

B. Ya.

Алексеев

Б. Я.

Russian Federation

Nyushko

K. M.

Нюшко

К. М.

Russian Federation

ФГУ Московский научно-исследовательский онкологический институт им. П.А. Герцена

30062007

61630303202003032020

https://oncourology.abvpress.ru/oncur/article/view/1265

1. Чиссов В.И., Старинский В.В. Онкологическая заболеваемость в России в 2004 году. М.; 2005.

Чиссов В.И., Старинский В.В. Онкологическая заболеваемость в России в 2004 году. М.; 2005.

2. Матвеев В.Б. Клиническая онкоурология. М.; 2003. с. 525—70.

Матвеев В.Б. Клиническая онкоурология. М.; 2003. с. 525—70.

3. Heidenreich A., Varga Z., von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003;169(3):1090.

Heidenreich A., Varga Z., von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2003;169(3):1090.

4. Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445—51.

Partin A.W., Kattan M.W., Subong E.N. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445—51.

5. Frei III E., Gehan E.A. Definition of cure for Hodgkin's disease. Cancer Res 1971;31:1828—33.

Frei III E., Gehan E.A. Definition of cure for Hodgkin's disease. Cancer Res 1971;31:1828—33.

6. Huggins C., Hoges C.V. Studies on prostatic cancer; I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. 1941. J Urol 2002;168(1):9—12.

Huggins C., Hoges C.V. Studies on prostatic cancer; I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. 1941. J Urol 2002;168(1):9—12.

7. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103—6.

Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103—6.

8. Bolla M., Maingon P., Fourneret P. et al. Indications of the association of radiotherapy and hormonal treatment in prostate cancer. Cancer Radiother 2005;9(6-7):394—8. Epub 2005 Oct 11.

Bolla M., Maingon P., Fourneret P. et al. Indications of the association of radiotherapy and hormonal treatment in prostate cancer. Cancer Radiother 2005;9(6-7):394—8. Epub 2005 Oct 11.

9. Bolla M. Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes? Nat Clin Pract Urol 2005;2(11):536—7.

Bolla M. Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes? Nat Clin Pract Urol 2005;2(11):536—7.

10.

10. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.

Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.

11.

11. Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;170(5):1955; author reply 1955—6.

Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;170(5):1955; author reply 1955—6.

12.

12. Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243—52.

Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243—52.

13.

13. Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

14.

14. Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.

Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.

15.

15. Pilepich M.V., Winter K., Lawton C.A. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

Pilepich M.V., Winter K., Lawton C.A. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

16.

16. Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic nodepositive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800—7.

Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic nodepositive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800—7.

17.

17. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972—8.

Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972—8.